Short Communication

FACTOR X-ACTIVATING ACTIVITY FROM LEWIS LUNG CARCINOMA

P. HILGARD* and P. WHUR†

From the *Department of Haematology, Royal Postgraduate Medical School, London W12, and the †Cell Biology Unit, Marie Curie Memorial Foundation, Oxled, Surrey

Received 10 December 1979 Accepted 2 January 1980

The procoagulant activity elicited by some experimental tumours was recently characterized as a Factor X-activating enzyme (Curatolo et al., 1979) and it was shown that this thromboplastic activity was clearly different from the Factor VII-dependent activity of most other tissues (Gordon et al., 1975). Since this activity appeared in serum-free media of fibroblasts after chemical transformation, it was suggested that it might even represent a marker of malignancy (Gordon & Lewis, 1978).

Factor X-activating activity was determined in two established Lewis lung carcinoma (3LL) cell lines which were free of any contaminating host cells. Washed cells from cultured primary tumours and spontaneous lung metastases were transferred to serum-free media containing unsupplemented Dulbecco’s medium without indicator and 20 mg/ml human Factor IX complex (prepared by the Plasma Fractionation Laboratory, The Churchill Hospital, Oxford). This preparation (Batch No. 9D1250) contained negligible amounts of Factor VII, 36 iu Factor IX, 52 u Factor II and 30 u Factor X reconstituted ml. The chromogenic substrate S-2222 (Kabi Vitrum Ltd, London) was added to the culture medium in a final concentration of 1 mm. After 2 h of incubation the optical density was read at 405 nm in a spectrophotometer. Appropriate controls consisted of cell-free as well as Factor X-free samples. The positive control contained 50 mg/ml Russell’s Viper venom instead of tumour cells. The results were expressed as arbitrary units derived from the optical densities generated by 2.7 x 10⁵ cells; they are summarized in Table I. As can be seen, only Russell’s Viper venom, which is known to be a potent direct activator of Factor X, and tumour cells, produced appreciable amounts of proteolytic activity. There was no statistical difference between the levels of Factor X activator detected in cultured primary and metastatic cells.

After transplantation of freshly suspended 3LL cells derived from a primary tumour into the upper thigh of 12 C57BL mice, 6 animals were treated with the vitamin K antagonist phenprocoumon throughout tumour growth, as previously described (Hilgard et al., 1977). Twelve days after transplantation the primary tumour was surgically removed and the animals were allowed to survive until Day 29. They were then killed and the secondary lung tumours carefully excised.

The primary tumours, lung tumours and fragments of abdominal muscle were homogenized and sonicated in normal saline. The protein content of each tissue extract was adjusted to 20 g/l with saline. all extracts were tested for clot-promoting activity using Factor VII-, Factor VIII- and Factor X-deficient human plasma as described by Curatolo et al. (1979).

Table II gives the mean clotting times obtained with different tissue extracts. Considerable thromboplastic activity of all tissues was found when tested in
Table I.—Factor X-activating activity measured with chromogenic substrate in primary and metastases using test plasma with specific clotting factor deficiencies. It is interesting to note that phenprocoumon treatment of the tumour-bearing animals produced a significant decrease of Factor X-activating activity, indicating that this proteolytic enzyme is vitamin-K-dependent. No significant differences between primary and secondary tumours could be established by either method.

The biological significance of the described procoagulant activity in cancer cells is unknown. Previous investigations have shown that warfarin (Poggi et al., 1978), phenprocoumon (Hilgard et al., 1977) and diet-induced vitamin K deficiency (Hilgard, 1977) inhibit primary tumour growth as well as the formation of spontaneous metastases of 3LL. The decreased synthesis of the procoagulant, Factor X-activating activity in anticoagulated and vitamin K-deficient animals indicates that the presence of this enzyme in tumour cells might facilitate the primary and metastatic growth of malignant tumours. This assumption accords with the current concept of the role of fibrin formation in tumour growth (Roos & Dingemans, 1979) and provides an additional rationale for the use of vitamin K antagonists in cancer therapy.

REFERENCES

CURATOLLO, L., COLOCCI, M., CAMBINI, A. L. & 4 others (1979) Evidence that cells from experimental tumours can activate coagulation Factor X. Br. J. Cancer, 40, 228.

GORDON, S. G., FRANKS, J. J. & LEWIS, B. (1975) Cancer Procoagulant A: A Factor X activating procoagulant from malignant tissue. Thromb. Res., 6, 127.

GORDON, S. G. & LEWIS, B. J. (1978) Comparison of procoagulant activity in tissue culture medium from normal and transformed fibroblasts. Cancer Res., 38, 2467.

HILGARD, P. (1977) Experimental vitamin K deficiency and spontaneous metastases. Br. J. Cancer, 35, 891.

HILGARD, P., SCHULTE, H., WETZIG, G., SCHMITT, G. & SCHMITT, C. G. (1977) Oral anticoagulation in the treatment of a spontaneously metastasizing murine tumour. Br. J. Cancer, 35, 78.

POGGI, A., MUSSONI, L., KORNBLIHTT, L., BALLABIO, E., DE GAETANO, G. & DONATI, M. B. (1978) Warfarin enantiomers, anticoagulation and experimental tumour metastasis. Lancet, i, 163.

ROOS, E. & DINGEMANS, K. P. (1979) Mechanisms of metastasis. Biochim. Biophys. Acta, 560, 135.